AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2019-11-24
Target enrollment:
Participant gender:
Summary
The CENTAUR trial was a 2:1 (active:placebo) randomized, double-blind, placebo-controlled
Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS.
Phase:
Phase 2
Details
Lead Sponsor:
Amylyx Pharmaceuticals Inc.
Collaborators:
ALS Association ALS Finding a Cure ALS Finding a Cure Foundation Leandro P. Rizzuto Foundation Massachusetts General Hospital Neurology Clinical Research Institute Neurological Clinical Research Institute at Massachusetts General Hospital Northeast ALS Consortium